Allogeneic osteoblastic cell therapy - Bone Therapeutics

Drug Profile

Allogeneic osteoblastic cell therapy - Bone Therapeutics

Alternative Names: ALLOB; ALLOB implantation

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Bone Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteonecrosis; Osteogenesis imperfecta
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fracture; Intervertebral disc degeneration

Most Recent Events

  • 05 Oct 2016 Updated efficacy data from a phase IIa trial in Intervertebral disc degeneration released by Bone Therapeutics
  • 16 Sep 2016 Pharmacodynamics data from a preclinical trial in Fracture treatment 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 24 Feb 2016 Efficacy data from a phase IIa trial in Intervertebral disc degeneration released by Bone Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top